Association of Mean Platelet Volume With Vascular Complications in the Patients With Type 2 Diabetes Mellitus

Krutik J. Brahmbhatt 1, Bharat Chaudhary 1, Darshankumar M. Raval 1, Shashwat Mallik 2, Shahin Khan 2, Mayur Patel 1, Nirav Patel 1

1. Internal Medicine, Medical College Baroda, Vadodara, IND 2. Medicine, Medical College Baroda, Vadodara, IND

Corresponding author: Shashwat Mallik, s.mallik8.9.2000@gmail.com

Abstract

Background

Diabetes mellitus (DM) is a global health concern that is predicted to involve over 10% of the adult population by the next decade. Vascular complications are the major source of mortality and morbidity in diabetics. Mean platelet volume (MPV) which indicates platelet activity may play a crucial role in the vascular effects of DM and, hence, can be used as a prognostic marker. We have attempted to study the association of MPV with the glycemic status, duration of diabetes, and presence of vascular complications in diabetics.

Methods

A cross-sectional study of 300 patients with type 2 DM aged ≥18 years admitted to the inpatient department of medicine was carried out in a tertiary care hospital. After subgrouping patients according to their glycemic status and MPV, the association between microvascular and macrovascular complications was studied.

Results

The majority of patients were >60 years of age and an increasing prevalence of vascular complications was noted with increasing age. Forty-six percent and 45% of the patients had microvascular and macrovascular complications, respectively. Ischemic heart disease (IHD) and retinopathy were the most common macrovascular and microvascular complications, respectively. Vascular complications in DM showed a significant association with MPV, fasting blood sugar (FBS), post-prandial blood sugar (PP2BS), glycated hemoglobin (HbA1c), and the duration of diabetes.

Conclusion

A high MPV was linked to poor glycemic control, a longer duration of diabetes, and an increased prevalence of vascular complications. Hence, MPV could be used as a cost-effective marker to predict vascular complications in patients with type 2 DM.

Introduction

Diabetes mellitus (DM) is a rapidly growing global health issue, which is a result of a problem with insulin secretion or its effect on the body. It is estimated to involve over 10% of the adult population by the end of the next decade, out of which a large chunk remains unaware of their diagnosis. Initially believed to be a lifestyle disease in the developed world, DM has now established itself in developing nations as well with three out of four adults with diabetes living in low to middle-income countries [1,2]. DM is characterized by chronic hyperglycemia due to the lack of insulin or its function, which causes endothelial dysfunction and negatively impacts vascular structures over the long term [3]. The vascular complications of type 2 DM are divided into microvascular and macrovascular complications, and both have shown an association with the glycemic control of patients. While atherosclerosis is one of the main causes of early mortality in DM, microvascular complications in DM like nephropathy and retinopathy are major contributors to chronic kidney disease and blindness worldwide [4]. These complications place a huge burden on the healthcare systems of countries, especially in developing nations like India.

Platelets are blood cells that are primarily involved in hemostasis by the formation of the primary platelet plug, which further leads to thrombus formation. Larger platelets are more active and contain more dense
granules which result in a stronger procoagulant effect and more thrombosis. Hence, the mean platelet volume (MPV) may have a causal association with the vascular complications seen in type 2 DM. But on the other hand, MPV may also be raised as a consequence of thrombotic events due to the rapid consumption of small platelets and rushed production of reticulated platelets by the bone marrow [5]. In either case, MPV could be used as a biomarker for vascular complications in type 2 DM. This could also be helpful as a cost-effective prognostic marker for type 2 DM in resource-limited settings. Apart from DM, a raised MPV is also seen in several cardiovascular and cerebrovascular events and intestinal diseases like Crohn’s disease. Similarly, a low MPV has also been described as a marker in diseases such as tuberculosis, ulcerative colitis, and several carcinomas [6].

In physiological conditions, a lower MPV corresponds to a higher platelet count and vice versa. But in pathologies with inflammation, there is a marked increase in thrombopoietin generation and activation of megakaryocytes by cytokines such as IL-6 which leads to a high platelet count along with large platelets. Hence, MPV has been suggested as a prognostic marker in various cardiovascular and cerebrovascular diseases as increased platelet activity leads to thrombotic events in susceptible individuals [6].

This study attempts to observe the correlation of MPV with vascular complications in diabetic patients. We have tried to determine whether platelets are activated in diabetes and its associated vascular complications by comparing the MPV between patients with vascular complications and those without them. The correlation of MPV with the glycemic status and duration of diabetes has also been studied. Additionally, we have attempted to observe the most common microvascular and macrovascular complications among diabetic patients.

**Materials And Methods**

A cross-sectional study was conducted in the department of medicine of a tertiary care hospital after taking due approval from the Institutional Ethics Committee of Biomedical and Health Research (#IECBHR/19-2021). After obtaining informed consent, the first 300 patients with type 2 DM (according to American Diabetes Association criteria) aged ≥18 years in the inpatient department of medicine were enrolled in the study [7]. Only patients who had been diagnosed with type 2 DM before the onset of signs and symptoms of vascular complications were included. Pediatric patients (<18 years), those with an abnormal platelet count (<100,000 or >400,000 platelets per microliter), those using drugs affecting platelet function, those with severe anemia (hemoglobin <8.0 g/dL) or hemoglobinopathies, pregnant females, or patients with acute or chronic infections, and chronic diseases or malignancies were excluded [8]. A detailed history was taken for each patient and a clinical examination was done for vascular complications.

The laboratory investigations done for each patient included a complete hemogram with MPV, blood urea, serum creatinine, urine routine microscopy, microalbuminuria test, coagulation profile, random blood sugar (RBS), fasting blood sugar (FBS), post-prandial blood sugar (PP2BS), glycated hemoglobin (HbA1c), echocardiography, lipid profile, and fundoscopy, while some other investigations like two-dimensional echocardiography, ultrasonography of kidney-ureter-bladder (USG-KUB), neuroimaging, and nerve conduction velocity study were done only if required. We measured the MPV and platelet counts with a complete blood count using an automated blood analyzer. The estimation of plasma glucose levels (FBS, PP2BS) was carried out by the glucose-oxidase method and that of HbA1c by the high-performance liquid chromatography method. After baseline evaluation, patients were sub-grouped according to their glycemic status and MPV, and their association with microvascular and macrovascular complications was studied.

Since the data was largely qualitative, the chi-square test was used. The analysis of data was done using MedCalc software (Ostend, Belgium: MedCalc Software Ltd.) and a p-value of <0.05 was considered statistically significant. receiver operating characteristic (ROC) curve analysis for age, FBS, HbA1c, and MPV for the diagnosis of vascular complications has been done using Microsoft Excel.

**Results**

Out of 300 patients with type 2 DM, there were 153 males and 147 females with a mean age of 53.96±12.17 years. The majority of the patients (35%) were >60 years of age while only 16% were aged <40 years. Majority of the patients had a FBS <200 mg/dL, PP2BS >350 mg/dL, HbA1c more than eight and MPV <12 fl. (Table 1).
| Variable      | Number of patients |
|--------------|--------------------|
| FBS (mg/dL)  |                    |
| <200         | 123                |
| 200-250      | 114                |
| 251-300      | 42                 |
| >300         | 21                 |
| PP2BS (mg/dL)|                    |
| <250         | 48                 |
| 251-300      | 72                 |
| 301-350      | 60                 |
| >350         | 120                |
| HbA1c        |                    |
| <8           | 39                 |
| 8.1-10       | 144                |
| 10.1-12      | 66                 |
| >12          | 51                 |
| MPV (fL)     |                    |
| 8-10         | 123                |
| 10-12        | 126                |
| >12          | 51                 |
| Duration of diabetes |          |
| <5 years     | 114                |
| 5-10 years   | 75                 |
| >10 years    | 111                |

**TABLE 1: Distribution of patients according to fasting blood sugar, post-prandial blood sugar, glycated hemoglobin, mean platelet volume, and duration of diabetes.**

FBS: fasting blood sugar; PP2BS: post-prandial blood sugar; HbA1c: glycated hemoglobin; MPV: mean platelet volume

Microvascular complications were present in 138 patients while macrovascular complications were recorded in 135 patients. Among microvascular complications, retinopathy was the most common (43%), followed by neuropathy (37%) and nephropathy (20%). Among macrovascular complications, ischemic heart disease (IHD) was the most common (41%), followed by cerebrovascular accidents (CVA) (36%) and peripheral vascular disease (PVD) (23%).

While gender did not have any association with the presence of vascular complications, a significant rise in both microvascular and macrovascular complications was noted with increasing age (p <0.001) (Table 2).
| Variables      | Microvascular complication | p-Value |
|----------------|-----------------------------|---------|
|                | Yes | No |
| Age-group      |     |    |   |
| <40 years      | 3   | 45 | <0.001 |
| 40-50 years    | 9   | 54 |
| 51-60 years    | 39  | 36 |
| >60 years      | 87  | 27 |
| Gender         |     |    |   |
| Male           | 72  | 81 | 0.7073 |
| Female         | 66  | 81 |
| Variables      | Macrovascular complication | p-Value |
|                | Yes | No |
| Age-group      |     |    |   |
| <40 years      | 0   | 51 | <0.001 |
| 40-50 years    | 3   | 63 |
| 51-60 years    | 42  | 36 |
| >60 years      | 90  | 15 |
| Gender         |     |    |   |
| Male           | 66  | 87 | 0.5082 |
| Female         | 69  | 78 |

**TABLE 2: Association of microvascular and macrovascular complications with sociodemography.**

Significant associations were found between microvascular complications and increasing FBS, PP2BS, HbA1c, MPV, and duration of diabetes (Table 3). Macrovascular complications were also significantly correlated with these parameters (Table 4). Out of the 117 patients having a high HbA1c (>10), 51 had an MPV >12 fL while 66 had an MPV <12 fL. In the subgroup of MPV >12 fL (HbA1c >10), 45 out of 51 patients had microvascular complications and 39 out of 51 patients had macrovascular complications (p >0.05). In the subgroup of MPV <12 fL (HbA1c >10), 39 out of 66 patients had microvascular complications, and 42 out of 66 patients had macrovascular complications (p >0.05).
| Variables         | Microvascular complication | p-Value |
|-------------------|----------------------------|---------|
|                   | Yes | No |         |
| FBS (mg/dL)       |     |    |         |
| <200              | 30  | 93 | <0.001  |
| 200-250           | 60  | 54 |         |
| 251-300           | 33  | 9  |         |
| >300              | 15  | 6  |         |
| PP2BS (mg/dL)     |     |    |         |
| <250              | 9   | 39 | <0.001  |
| 251-300           | 21  | 51 |         |
| 301-350           | 24  | 36 |         |
| >350              | 84  | 36 |         |
| HbA1c             |     |    |         |
| <8                | 3   | 36 |         |
| 8-10              | 51  | 93 | <0.0001 |
| 10.1-12           | 39  | 27 |         |
| >12               | 45  | 6  |         |
| MPV (fl)          |     |    |         |
| 8-10              | 21  | 102| <0.0001 |
| 10-12             | 72  | 54 |         |
| >12               | 45  | 6  |         |
| Duration of diabetes |     |    |         |
| <5 years          | 6   | 108|         |
| 5-10 years        | 39  | 36 | <0.0001 |
| >10 years         | 93  | 18 |         |

TABLE 3: Association of microvascular complications with fasting blood sugar, post-prandial blood sugar, glycated hemoglobin, mean platelet volume, and duration of diabetes.

FBS: fasting blood sugar; PP2BS: post-prandial blood sugar; HbA1c: glycated hemoglobin; MPV: mean platelet volume
| Variables          | Macrovascular complication | p-Value |
|-------------------|----------------------------|---------|
|                   | Yes | No |         |
| FBS (mg/dL)       |     |    |         |
| <200              | 24  | 99 | <0.0001 |
| 200-250           | 66  | 48 |         |
| 251-300           | 27  | 15 |         |
| >300              | 18  | 3  |         |
| PP2BS (mg/dL)     |     |    |         |
| <250              | 6   | 42 | <0.0001 |
| 251-300           | 21  | 51 |         |
| 301-350           | 21  | 39 |         |
| >350              | 87  | 33 |         |
| HbA1c             |     |    |         |
| <8                | 9   | 30 |         |
| 8-10              | 45  | 99 | <0.0001 |
| 10.1-12           | 36  | 30 |         |
| >12               | 45  | 6  |         |
| MPV (fL)          |     |    |         |
| 8-10              | 27  | 96 | <0.0001 |
| 10-12             | 69  | 57 |         |
| >12               | 39  | 12 |         |
| Duration of diabetes |     |    |         |
| <5 years          | 3   | 111|         |
| 5-10 years        | 30  | 45 | <0.0001 |
| >10 years         | 102 | 9  |         |

**TABLE 4: Association of macrovascular complications with fasting blood sugar, post-prandial blood sugar, glycated hemoglobin, mean platelet volume, and duration of diabetes.**

FBS: fasting blood sugar; PP2BS: post-prandial blood sugar; HbA1c: glycated hemoglobin; MPV: mean platelet volume

An increase in the duration of diabetes was accompanied by an increase in the MPV with a correlation coefficient (r) of 0.6521. A similar correlation of MPV was seen with FBS (r=0.5649), PP2BS (r=0.5712), and HbA1c (r=0.6627) (Figures 1-4).
FIGURE 1: Correlation between duration of diabetes and mean platelet volume.

MPV: mean platelet volume

FIGURE 2: Correlation between fasting blood sugar and mean platelet volume.

FBS: fasting blood sugar; MPV: mean platelet volume

FIGURE 3: Correlation between post-prandial blood sugar and mean platelet volume.

PP2BS: post-prandial blood sugar; MPV: mean platelet volume
FIGURE 4: Correlation between glycated hemoglobin and mean platelet volume.

HbA1c: glycated hemoglobin; MPV: mean platelet volume

ROC analysis of age, FBS, HbA1c, and MPV for the diagnosis of both microvascular and macrovascular complications was done (Table 5, Figures 5-12).
## TABLE 5: Receiver operating characteristic analysis with area under the curve.

AUC: area under the curve; FBS: fasting blood sugar; HbA1c: glycated hemoglobin; MPV: mean platelet volume

| Microvascular complications | Cut-off | Macrovascular complications |
|-----------------------------|---------|-----------------------------|
| Total AUC                   | AUC     | Youden index | Specificity | Sensitivity | Specificity | Youden index | AUC | Total AUC     |
| **Age (years)**             |         |              |             |             |             |              |     |               |
| 0.7712                      | 0.2320  | 0.0432       | 0.0432      | 1           | >30         | 1             | 0.0303 | 0.0303        | 0.2787 |
|                             | 0.3152  | 0.2560       | 0.2777      | 0.9782      | >40         | 1             | 0.3090 | 0.3090        | 0.3775 |
|                             | 0.1714  | 0.5241       | 0.6111      | 0.9130      | >50         | 0.9777        | 0.6909 | 0.6686        | 0.1793 |
|                             | 0.0523  | 0.4637       | 0.8333      | 0.6304      | >60         | 0.666         | 0.9090 | 0.5757        | 0.0303 |
| **FBS (mg/dL)**             |         |              |             |             |             |              |     |               |
| 0.6927                      | 0.4896  | 0.0248       | 0.0246      | 1           | >90         | 1             | 0.0006 | 0.0006        | 0.4914 |
|                             | 0.1884  | 0.3566       | 0.5740      | 0.7826      | >200        | 0.6222        | 0.6000 | 0.4222        | 0.1680 |
|                             | 0.0126  | 0.2552       | 0.9074      | 0.3478      | >250        | 0.3333        | 0.8909 | 0.2242        | 0.0212 |
|                             | 0.0020  | 0.0716       | 0.9629      | 0.1086      | >300        | 0.1333        | 0.9828 | 0.1151        | 0.0012 |
| **HbA1c**                   |         |              |             |             |             |              |     |               |
| 0.7470                      | 0.2075  | 0.0123       | 0.0123      | 1           | >6.4        | 1             | 0.0121 | 0.0121        | 0.1640 |
|                             | 0.4555  | 0.2004       | 0.2004      | 0.9782      | >8          | 0.9333        | 0.1818 | 0.1151        | 0.4600 |
|                             | 0.0778  | 0.4049       | 0.4049      | 0.6086      | >10         | 0.6000        | 0.7818 | 0.3818        | 0.0848 |
|                             | 0.0060  | 0.2890       | 0.2890      | 0.3260      | >12         | 0.3333        | 0.9636 | 0.2969        | 0.0060 |
| **MPV (fL)**                |         |              |             |             |             |              |     |               |
| 0.7834                      | 0.5817  | 0             | 0           | 1           | >8          | 1             | 0      | 0              | 0.5236 |
|                             | 0.1956  | 0.4774       | 0.6296      | 0.8478      | >10         | 0.8000        | 0.5818 | 0.3818        | 0.1880 |
|                             | 0.0080  | 0.2890       | 0.9629      | 0.3260      | >12         | 0.2888        | 0.9272 | 0.2161        | 0.0105 |

2022 Brahmbhatt et al. Cureus 14(9): e29316. DOI 10.7759/cureus.29316
**FIGURE 5:** Receiver operating characteristic curve for age in diagnosing microvascular complications.

TPR: true positivity rate; FPR: false positivity rate

**FIGURE 6:** Receiver operating characteristic curve for age in diagnosing macrovascular complications.

TPR: true positivity rate; FPR: false positivity rate
FIGURE 7: Receiver operating characteristic curve for fasting blood sugar in diagnosing microvascular complications.

TPR: true positivity rate; FPR: false positivity rate

FIGURE 8: Receiver operating characteristic curve for fasting blood sugar in diagnosing macrovascular complications.

TPR: true positivity rate; FPR: false positivity rate
FIGURE 9: Receiver operating characteristic curve for glycated hemoglobin in diagnosing microvascular complications.
TPR: true positivity rate; FPR: false positivity rate

FIGURE 10: Receiver operating characteristic curve for glycated hemoglobin in diagnosing macrovascular complications.
TPR: true positivity rate; FPR: false positivity rate
Discussion

The most morbid complications of type 2 DM are vascular, which severely affect the life span as well as the quality of life in patients, along with increasing the health expenditure for complications that can be easily prevented by intensive glycemic control [1,4]. The economic burden of the disease is detrimental to middle-
income countries like India, which is expected to remain a major contributor to the disease in the future, and, hence, early detection and prognosis of these vascular events with accessible and affordable biomarkers is the need for the hour [9]. This study attempts to evaluate the glycemic status and MPV as potential biomarkers for vascular complications in type 2 DM.

A study from Saudi Arabia found that microvascular complications like retinopathy, nephropathy, and neuropathy were present in 15%, 14.8%, and 5.6% of diabetic patients, respectively, while macrovascular complications like IHD and CVA were present in 8% and 6% patients, respectively [10]. A study from South India reported the prevalence of microvascular and macrovascular complications to be 52.1% and 29.7%, respectively. Neuropathy was the most common microvascular complication and coronary artery disease and PVD were the most common macrovascular complications [11]. Another study from Sudan reported nephropathy to be the most common microvascular complication among type 2 diabetics [12]. In contrast, our study found that microvascular and macrovascular complications were present in 46% and 45% of diabetic patients, respectively. Retinopathy and IHD were the most common microvascular and macrovascular complications in this study. Similar to our study, advancing age is associated with more vascular complications [13-16]. Some studies have shown that elderly males with type 2 diabetes have a higher rate of IHD than similarly aged females, and female diabetics are more prone to diabetic retinopathy than their male counterparts [14,16], but no such association of vascular complications with gender was found in our study. A higher risk of vascular complications has been attributed to poor glycemic control and a longer duration of diabetes, which is in concordance with our results [15,17,18]. A study intended to identify the association between diabetic vascular complications with the duration of DM supported our findings (hazard ratio=1.3, confidence interval=1.08 to 1.17) [17]. A study used FBS >152 mg/dL as the criterion for poor glycemic control, which had a positive association with the prevalence of diabetic complications [18].

Increased platelet activity has been hypothesized to be a crucial factor in the development of vascular complications in type 2 DM. A marker of platelet function, the MPV has been widely used to study platelet activation in the disease. Younger and more active platelets which can easily aggregate have a higher MPV, while lesser active platelets have lower MPV [5,19,20]. Several studies have shown a significant association of MPV with FBS, PP2BS, and HbA1c which is in concordance with our results [21-23]. A study aimed at seeing the correlation between MPV and blood glucose level after glucose loading in normoglycemic and prediabetic patients suggested that there was a positive correlation between MPV and the post-challenge glucose level after two hours [24]. A meta-analysis of MPV levels in diabetic retinopathy revealed that MPV levels were significantly higher in patients with diabetic retinopathy as compared to those without diabetic retinopathy [25]. Our study found that higher values of MPV were associated with a higher prevalence of microvascular and macrovascular complications, which is similar to other studies [26,27]. But, on stratification of MPV with high HbA1c (>10), the significant association with vascular complications was lost. Additionally, a high MPV is not only associated with vascular complications in type 2 DM but also in non-diabetics. The increased thrombogenic potential due to raised MPV has resulted in worse outcomes in acute ischemic stroke patients. It has also emerged as an independent risk factor for myocardial infarction. In coronary artery disease patients with a high MPV, the baseline thrombogenicity is increased and in case the atherosclerotic plaque ruptures, the large platelets rapidly form a thrombus leading to occlusion of the artery [28,29]. Thus, MPV may be crucial in predicting vascular complications even in diabetics with satisfactory glycemic control.

Since the sample population was largely from Western and Central India, a multicentric prospective study should be conducted for the generalizability of these results which could also include other platelet indices like platelet distribution width and platelet large cell ratio. All patients in this study were indoor cases and, hence, most had poor glycemic control and diabetic complications. Consequently, the number of patients with good glycemic control was very less and the prevalence of vascular complications may be falsely inflated. Though hyperglycemia may play a role in the prothrombotic state, the independent association of MPV with vascular complications should not be ruled out as this association has also been seen in those without type 2 DM. While the association of MPV with vascular complications in type 2 DM should be unquestionable, the cross-sectional nature of this study further prevents determining whether raised MPV is a causative factor for vascular complications including atherosclerosis, or is a byproduct of them.

Conclusions

Poor glycemic control indicated by a high FBS, PP2BS, or HbA1c along with a longer duration of diabetes were all linked to a higher risk of vascular complications in patients of type 2 DM. A high MPV was also found to be significantly associated with microvascular and macrovascular complications and also has a strong correlation with FBS, PP2BS, HbA1c, and duration of diabetes. Hence, it could be used as a cost-effective marker to monitor for vascular complications in type 2 diabetic patients, especially in limited-resource settings. Even though MPV has a significant association with vascular complications, stratification of MPV with high HbA1c (>10) was not found to have a significant association with vascular complications.

Additional Information

Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of Biomedical and Health Research, Medical College and SSG Hospital Baroda issued approval #IECBHR/19-2021. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. IDF Diabetes Atlas. (2022). Accessed: July 22, 2022: http://www.diabetesatlas.org.
2. Saeedi P, Petersohn I, Salpea P, et al.: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019, 157: 10106/j.diarres.2019.107845
3. Singh P, Choudhary R, Singh VK, Mateja P: Comparison of metabolic effects of glimepiride and sitagliptin with metformin in patients suffering from type 2 diabetes mellitus in a tertiary care hospital. Int J Basic Clin Pharmacol. 2019, 8:1467-72. 10.18205/2399-2005.ijbcp20192645
4. Rask-Madsen C, King GL: Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2015, 17:20-33. 10.1016/j.cmet.2012.11.012
5. Mitchell RN, Kumar V, Abbas AK, Fausto N, Aster J: Hemodynamic disorders, thromboembolic disease and shock. Pocket Companion to Robbins and Cotran Pathologic Basis of Disease. Eighth Edition. Kumar V (ed): Elsevier, Amsterdam, Netherlands; 2011. 66-83.
6. Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V: Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019, 2019: 10.1155/2019/9213074
7. Nathan DM, Balkau B, Bonora E, et al.: International expert committee report on the role of the AIC assay in the diagnosis of the diabetes. Diabetes Care. 2009, 32:1327-34. 10.2337/dc09-0933
8. Scharf RE: Drugs that affect platelet function. Semin Thromb Hemost. 2012, 38:865-83. 10.1055/s-0032-1268881
9. Diabetes. (2022). Accessed: July 22, 2022: http://www.who.int/mediacentre/factsheets/fs312/en/.
10. Alaaoud AF, Tourkmani AM, Alharbi T, et al.: Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia. Saudi Med J. 2016, 37:1408-11. 10.1557/smj.2016.12.17062
11. Govindarajan Vengdevasevare A, Jasmine K, Varadarajan S, et al.: Prevalence of vascular complications among type 2 diabetic patients in a rural health center in South India. J Prim Care Community Health. 2020, 11:10.1177/2150132720979962
12. Hussein M, Mansari S: Prevalence of microvascular complications in type 2 diabetes attending a primary healthcare centre in Sudan. Int J Diabetes Metab. 2019, 25:127-33. 10.1159/000500914
13. Shamshirgan SM, Mamaghani A, Aliagazrad ez, Aminisani N, Iranjbar-Alamdari M, Ataei J: Age differences in diabetes-related complications and glycemic control. BMC Endor Disorder. 2017, 17:10.1186/s12902-017-0175-5
14. Motta M, Beninati E, Feriloto L, Passamonte M, Branca S, Malaguarnera M: Cardio-cerebrovascular complications in elderly with diabetes. Arch Gerontol Geriatr. 2007, 44:261-9. 10.1016/j.archger.2006.05.005
15. Zhang X, Saadate M, Chou CF, et al.: Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010, 504:649-56. 10.1155/daya/10.1001/jama.2010.1111
16. Won JC, Kwon HS, Kim CH, Lee IH, Park TS, Ko KS, Cha HY: Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med. 2012, 29:290-6. 10.1111/j.1444-5444.2012.03679.x
17. Zoungas S, Woodward M, Li Q, et al.: Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014, 57:2465-74. 10.1007/s00125-014-3569-7
18. Fasiil A, Biado G, Abebe M: Glycemic control and diabetes complications among diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia. Diabetes Metab Syndr Obes. 2019, 12:75-83. 10.2147/DMSO.S165164
19. Colwell JA, Nesto RW: The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003, 26:2181-8. 10.2337/diacare.26.7.2181
20. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garpin T: The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications. 2009, 23:99-94. 10.1016/j.jdiacomp.2008.01.006
21. Saluja M, Swami VK, Meena SR: Study of impact of glycemic status (HbA1c) on platelet activity measured by mean platelet volume and vascular complications in diabetics. J Assoc Physicians India. 2019, 67:26-9. 10.1855/sjmscr/v92i2.58
22. Sharma A, Arora S, Singh S: Correlation of platelet indices with glycaemic control and vascular complications in diabetic patients in a tertiary hospital based study. J Med Sci Clin Res. 2021, 9:189-94. 10.18553/mscr/v92i2.50
23. Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S: Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011, 16:86-9. 10.1179/102453311X12902908412110
24. Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hamyu N, Nakayama T: Correlation between mean platelet volume and blood glucose levels after oral glucose loading in normoglycemic and prediabetic Japanese subjects. J Diabetes Investig. 2014, 5:66-71. 10.1111/jdi.12117
25. Ji S, Zhang J, Fan X, et al.: The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019, 11: 10.1186/s13098-019-0420-3

26. Cadirci K, Olcaysu O, Yigit D, Carlioglu A, Durmaz SA.: Mean platelet volume in type 2 diabetic patient: is there a relationship between mean platelet volume and diabetic microvasculatory complications?. Endocr Abstr. 2014, 35: 10.1550/endoabs.35.P448

27. Amer HM, Makboul KM, Mostafa BM, Giris CA, Mohammed YA.: The study of mean platelet volume (MPV) as a potential risk factor for macrovascular complications (ischemic heart disease and cerebrovascular stroke) in type 2 diabetes mellitus. QJM-Int J Med. 2020, 113: 10.1093/qjmed/hca052.024

28. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouscheck W.: Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke. 2004, 35: 1688-91. 10.1161/01.STR.0000130512.81212.a2

29. Endler G, Klimesch A, Sunder-Plassmann H, et al.: Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002, 117: 399-404. 10.1046/j.1365-2141.2002.03441.x